Neuropsychological and conditioned blocking performance in patients with schizophrenia: assessment of the contribution of neuroleptic dose, serum levels and dopamine D2-receptor occupancy [PDF]
, 2000 Robert D. Oades +4 more
openalex +1 more source
Management of Anxiety in Parkinson's Disease
Movement Disorders Clinical Practice, Volume 12, Issue 10, Page 1490-1501, October 2025.ABSTRACT Background Anxiety is a common, distressing, hard‐to‐diagnose and hard‐to‐treat symptom in Parkinson's disease. No formal guidelines exist to assist management. Objective We provide a pragmatic guide to detecting and managing anxiety in Parkinson's disease.
Alex J. Berry +4 more
wiley +1 more source
D1-D2 Dopamine Receptor Synergy Promotes Calcium Signaling via Multiple Mechanisms
Molecular Pharmacology, 2013 L. Chun +5 more
semanticscholar +1 more source
Genetic polymorphism of dopamine D2 receptors in Parkinson's disease and interactions with cigarette smoking and MAO-B intron 13 polymorphism [PDF]
, 2000 Paola Costa‐Mallen
openalex +1 more source
Surprises From the Basal Ganglia: Stop and Go Have New Meaning
Movement Disorders, Volume 40, Issue 10, Page 2077-2082, October 2025.Abstract This perspective highlights new work suggesting the need for revision of the canonical direct–indirect model of the basal ganglia's influence on movement, with fresh evidence that there is a formerly unappreciated pair of direct and indirect pathways that parallel the standard model's canonical direct and indirect pathways, and promising ...
Ann M. Graybiel
wiley +1 more source
Case-Control Study of the D2 Dopamine Receptor Gene and Smoking Status in Lung Cancer Patients
, 1998 Margaret R. Spitz +10 more
openalex +1 more source
In vitro and in vivo evaluation of the binding of the dopamine D2 receptor agonist11C-(R,S)-5-hydroxy-2-(di-n-propylamino)tetralin in rodents and nonhuman primate [PDF]
, 2000 Jogeshwar Mukherjee +5 more
openalex +1 more source
Dopaminergic drug response and the genotype (Taq IA polymorphism) of the dopamine D2 receptor [PDF]
, 2000 Ivan Berlin +5 more
openalex +1 more source
Neuroinflammation drives apathy in cancer cachexia
Cancer Communications, Volume 45, Issue 10, Page 1334-1337, October 2025.
Bingjun Ha, Xuetao Cao
wiley +1 more source
CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 10, Page 1695-1704, October 2025.ABSTRACT A physiologically based pharmacokinetic (PBPK) model was developed and verified for dordaviprone, a small molecule with antitumor effects in glioma patients. The model was applied to assess the drug–drug interaction (DDI) potential of dordaviprone as a victim of CYP3A4 inhibitors and inducers, and as a perpetrator of CYP3A4, CYP2C8, CYP2D6 ...
Swati Jaiswal +6 more
wiley +1 more source